CD73: a new biomarker in triple-negative breast cancer

Abstract : Triple-negative breast cancer (TNBC) constitute 10–20% of all breast cancers and are characterized by the lack of hormone receptors (estrogen and progesterone receptors) and HER2/neu expression (1). TNBC are not eligible to hormonotherapy and Herceptin/trastuzumab targeted therapy and are generally associated with poor clinical outcome (2). Anthracycline/taxane-based neoadjuvant chemotherapy is the primary systemic treatment but resistance to this treatment is common and the identification of new potential therapeutic molecules is required to improve the outcome of TNBC patients.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02289836
Contributeur : Anthony Herrada <>
Soumis le : mardi 17 septembre 2019 - 10:49:47
Dernière modification le : mercredi 18 septembre 2019 - 01:22:17

Identifiants

Collections

Citation

Virginie Lafont, Henri-Alexandre Michaud, Nathalie Bonnefoy. CD73: a new biomarker in triple-negative breast cancer. Translational Cancer Research, AME Group, 2018, 7 (S5), pp.S594-S596. ⟨10.21037/tcr.2018.05.22⟩. ⟨hal-02289836⟩

Partager

Métriques

Consultations de la notice

17